96% up by HPLC, USP, GMP Atracurium Besylate 64228-81-5 | Pharmaceutical Materials

Product Catagories

Medical Raw Materials

首页 > Pharmaceutical Materials > 96% up by HPLC, USP, GMP Atracurium Besylate 64228-81-5

96% up by HPLC, USP, GMP Atracurium Besylate 64228-81-5

单价	面议对比
询价	暂无
发货	全国
过期	长期有效
更新	2025-08-13 23:43

详细信息

Grade: Pharmaceutical Grade

Factory Location: Xiamen, Fujian

Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East

Monthly Production Capacity: 1000kg

Packaging Information: 25kg/drum 1kg/bottle

Delivery Lead Time: 7 days after payment

Sample Provided: yes

Payment Terms: L/L

Product Information

Product name	Atracurium Besylate
CAS No.	64228-81-5
Molecular Formula	C53H72N2O12.2(C6H5O3S)
Molecular Weight	257.60
Quality Standard	96% up by HPLC, GMP,USP
Appearance	White or almost white powder

COA of Atracurium Besylate

ITEMS	SPECIFICATION	RESULT
Appearance:	white or almost white powder, slightly hygroscopic, ordorless	Confirms
Appearance:	Very solutable in acetonitrile or chloroform, Soluble in Water, very soluble and practically insolutable in ethyl ether	Confirms
Identification	(1) IR	Conforms
Identification	(2) HPLC	Conforms
Water	≤ 5.0%	0.6%
Residue on ignition	≤ 0.2%	0.1%
Methyl benzenesulfonate	≤ 0.1%	Undetected
Toluene	≤ 890ppm (ICH)	102ppm
Chromatographic purity	(1) Laudanosine: ≤ 0.5% (2) Other individual impurities: ≤ 1.0% (3) Total Impurities: ≤ 3.5%	0.01% 0.38% 1.3%
Isomer Ratio	Trans-Trans Isomer: 5%-6.5%	5.7%
	Cis-Trans Isomer: 34.5%-38.5%	36%
	Cis-Cis Isomer: 55%-60%	58.2%
Assay	96%-102% (C65H82N2O18S2 on anhydrous basis)	100.2%
Residue Solvents	(1) Dichloromethane: ≤ 600ppm (2) Acctonitrile: ≤ 410ppm (3) Ethyl ether: ≤ 5000ppm	Undetected Undetected 1739ppm
Result	Confirms to USP34

Usage

Function of Atracurium Besylate

Atracurium besylate is a skeletal muscle relaxant for general anesthesia, suitable for the treatment of muscle relaxation for endotracheal intubation and for muscle relaxation required for thoracic and abdominal surgery. Like most neuromuscular blocking agents, it can Causes the release of histamine, skin flushing, transient hypotension, and occasionally bronchospasm. Caution should be used in patients with myasthenia gravis, neuromuscular disease, and severe electrolyte disturbances, as it potentiates the effects of other non-depolarizing agents. People with severe cardiovascular disease are more sensitive to the transient hypotensive reaction of this product, so it is recommended to give slow intravenous injection in divided doses.

Product Information

Product name

Atracurium Besylate

CAS No.

64228-81-5

Molecular Formula

C53H72N2O12.2(C6H5O3S)

Molecular Weight

257.60

Quality Standard

96% up by HPLC, GMP,USP

Appearance

White or almost white powder

COA of Atracurium Besylate

ITEMS

SPECIFICATION

RESULT

Appearance:

white or almost white powder,

slightly hygroscopic, ordorless

Confirms

Very solutable in acetonitrile or chloroform, Soluble in Water, very soluble and practically insolutable in ethyl ether

Confirms

Identification

(1) IR

Conforms

(2) HPLC

Conforms

Water

≤ 5.0%

0.6%

Residue on ignition

≤ 0.2%

0.1%

Methyl benzenesulfonate

≤ 0.1%

Undetected

Toluene

≤ 890ppm (ICH)

102ppm

Chromatographic purity

(1) Laudanosine: ≤ 0.5%

(2) Other individual impurities: ≤ 1.0%

(3) Total Impurities: ≤ 3.5%

0.01%

0.38%

1.3%

Isomer Ratio

Trans-Trans Isomer: 5%-6.5%

5.7%

Cis-Trans Isomer: 34.5%-38.5%

36%

Cis-Cis Isomer: 55%-60%

58.2%

Assay

96%-102%

(C65H82N2O18S2 on anhydrous basis)

100.2%

Residue Solvents

(1) Dichloromethane: ≤ 600ppm

(2) Acctonitrile: ≤ 410ppm

(3) Ethyl ether: ≤ 5000ppm

Undetected

Undetected

1739ppm

Result

Confirms to USP34

Usage

Function of Atracurium Besylate